Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
International Journal of Clinical Pharmacology and Therapeutics
|
July 31, 2020
Pharmacokinetics, pharmacodynamics, and tolerability of JY09 in healthy Chinese subjects: A titrating, dose-escalating study
Guangyu Yang, Bei Cao, Yuanxun Yang, et al.
Frontiers in Pharmacology
|
December 29, 2022
First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody
Tingting Ma, Bei Cao, Lei Huang, et al.
Scientific Reports
|
January 3, 2025
ALKBH5 acts a tumor-suppressive biomarker and is associated with immunotherapy response in hepatocellular carcinoma
Hehua Ma, Yuxin Hong, Zhenzhen Xu, et al.
Expert Opinion on Investigational Drugs
|
August 21, 2024
The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects
Tingting Ma, Zuyi Weng, Bei Cao, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
March 7, 2024
N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) modification in hepatocellular carcinoma
Hehua Ma, Yuxin Hong, Zhenzhen Xu, et al.
Molecular Genetics and Genomics : MGG
|
March 1, 2023
Metabolomics analysis reveals cytotoxic effects of ouabain towards psoriatic keratinocytes via impairment of glutathione metabolism
Xuan Zhou, Fei Fei, Wei Song, et al.
Frontiers in Pharmacology
|
November 7, 2022
SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
Tingting Ma, Yanli Dong, Lei Huang, et al.
Diabetes, Obesity & Metabolism
|
September 25, 2025
Phase I study of the oral GLP-1 receptor agonist DA-302168S: Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults
Liang Zheng, Yuanxun Yang, Guangxin Dong, et al.
Frontiers in Pharmacology
|
May 14, 2024
The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses
Yuanxun Yang, Lei Yu, Zejuan Sheng, et al.
BMC Medicine
|
May 28, 2024
Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study
Diaozhu Lin, Huisheng Xiao, Kexu Yang, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
International Journal of Clinical Pharmacology and Therapeutics
|
July 31, 2020
Pharmacokinetics, pharmacodynamics, and tolerability of JY09 in healthy Chinese subjects: A titrating, dose-escalating study
Guangyu Yang, Bei Cao, Yuanxun Yang, et al.
Frontiers in Pharmacology
|
December 29, 2022
First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody
Tingting Ma, Bei Cao, Lei Huang, et al.
Scientific Reports
|
January 3, 2025
ALKBH5 acts a tumor-suppressive biomarker and is associated with immunotherapy response in hepatocellular carcinoma
Hehua Ma, Yuxin Hong, Zhenzhen Xu, et al.
Expert Opinion on Investigational Drugs
|
August 21, 2024
The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects
Tingting Ma, Zuyi Weng, Bei Cao, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
March 7, 2024
N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) modification in hepatocellular carcinoma
Hehua Ma, Yuxin Hong, Zhenzhen Xu, et al.
Molecular Genetics and Genomics : MGG
|
March 1, 2023
Metabolomics analysis reveals cytotoxic effects of ouabain towards psoriatic keratinocytes via impairment of glutathione metabolism
Xuan Zhou, Fei Fei, Wei Song, et al.
Frontiers in Pharmacology
|
November 7, 2022
SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
Tingting Ma, Yanli Dong, Lei Huang, et al.
Diabetes, Obesity & Metabolism
|
September 25, 2025
Phase I study of the oral GLP-1 receptor agonist DA-302168S: Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults
Liang Zheng, Yuanxun Yang, Guangxin Dong, et al.
Frontiers in Pharmacology
|
May 14, 2024
The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses
Yuanxun Yang, Lei Yu, Zejuan Sheng, et al.
BMC Medicine
|
May 28, 2024
Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study
Diaozhu Lin, Huisheng Xiao, Kexu Yang, et al.
Page
of 2